Review Article

Clinical Screening Tools for Sarcopenia and Its Management

Table 1

Summary of currently available screening tools for sarcopenia.

EWGSOP algorithm [10]SARC-F questionnaire [14]Goodman et al. [15]Ishii et al. [16]Anthropometric PE [17, 18]

DescriptionTwo-step algorithm: 
First step: gait speed  
Second step: handgrip strength if gait speed >0.8 m/s. If hand grip is low, proceed to muscle mass 
Muscle mass measurement if gait speed ≤0.8 m/s
Assessed 5 domains: Strength, independence walking, rising from a chair, climbing stairs, and history of falls  
Total score is 10 points (2 for each domain)  
A score of ≥4 indicates a risk for sarcopenia
Grid based on age and BMI is used to generate probability of sarcopenia which can be <0.20, 0.20–0.49 and ≥0.50To estimate probability of sarcopenia with a score chart using age, handgrip strength, and calf circumferencePE = 10.05 + 0.35 (weight) − 0.62 (BMI) − 0.02 (age) + 5.10 (if male)

Definition of sarcopeniaEWGSOPEWGSOP 
IWGS 
AWGS
Sarcopenia defined as low skeletal muscle index (SMI) [ASM/height2] <1 SD below the mean SMI of young adults (20–40 years)EWGSOPSarcopenia as defined by ASM and low grip strength  
Men:  
< 7.36 kg/m2
Grip strength < 30 kg 
Women: 
5.81 kg/m2
Grip strength < 20 kg

Development modelNANot published in a peer-reviewed journalDevelopment model from NHANES, USA 
Aged ≥ 65 years 
M = 3538 
F = 5272
Development model from Japanese community-dwellers  
Aged ≥ 65 years 
M = 977 
F = 994
Derived from healthy subject (age 18 to 83 years), Australia 

Validation studyNATwo studies: 
(a) Community dwellers in Hong Kong 
  
(b) Chinese older adults aged >65 years in various settings (i.e., community dwellers and nursing home residents) 
Independent sample from patients in the University of Utah Health Care System, USA 
Aged ≥65 years 
M = 103 
F = 103
Internal validation using bootstrapping procedure and final models were derived by correcting regression coefficient for over optimismIndependent sample from NWAHS and FAMAS community dwelling population adults ≥65 years  
M = 611 
F = 375

Sensitivity (%)NAEWGSOP
M 4.2 
W 9.9 
IWGS
M 3.8 
W 8.2 
AWGS
M 4.8 
W 9.4
M 81.2 
W 90.6
M 84.9 
W 75.5
M 88.2 
W 100.0

Specificity (%)NAEWGSOP
M 98.7 
W 94.4 
IWGS
M 99.1 
W 94.6 
AWGS
M 98.8 
W 94.2
M 66.2 
W 66.2
M 88.2 
W 92
M 95.5 
W 83.0

PPV (%)NAEWGSOP
M 25.8 
W 14.3 
IWGS
M 54.8 
W 25.2 
AWGS
M 29.0 
W 8.4
M 58.5 
W 54.7
M 54.4 
W 72.8
M 65.2 
W 29.2

NPV (%)NAEWGSOP
M 90.8 
W 91.8 
IWGS
M 78.4 
W 82.2 
AWGS
M 91.0 
W 94.4
M 86 
W 94
M 97.2 
W 93.0
M 98.8 
W 100.0

BMI: body mass index; EWGSOP: European Working Group on Sarcopenia in Older People; IWGS: International Working Group on Sarcopenia; AWGS: Asian Working Group for Sarcopenia; FAMAS: Florey Adelaide Male Aging Study; SARC-F: slowness, independence walking, rising from chair, climbing stairs, and history of falls questionnaire; NHANES: National Health and Nutrition Examination Surveys; NWAHS: Northwestern Adelaide Healthy Study; PE: prediction equation; : appendicular skeletal muscle mass as measured by anthropometric prediction equation; PPV: positive predictive value; NPV: negative predictive value; M: men; W: women.